Well, I would say that the previous marketcap (before the deal) was already baking in something other than continued losses, no?
regarding the derisking part, I dont quite understand it. If the company keeps its costs for the clinical trials + admin at 24M, to justify the current price (following my previous logic), the revenue coming from the clinical trials would have to be $30 million. I'm not saying it wont be even higher, but there was already one time when things didn't go according to plan,right? Can that happen again?
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.72 |
Change
-0.030(1.71%) |
Mkt cap ! $290.5M | |||
| Open | High | Low | Value | Volume |
| $1.75 | $1.75 | $1.71 | $18.31K | 10.61K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 2488 | $1.71 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.74 | 1545 | 1 |
View Market Depth
| Last trade - 10.30am 02/07/2025 (20 minute delay) ? |
| CGS (ASX) Chart |